Lapatinib plus paclitaxel as first-line therapy for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: inappropriate conclusions from a company-sponsored study?
Amir
Eitan
E
Seruga
Bostjan
B
Freedman
Orit
O
Tannock
Ian
I
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000556:secondary; D005260:Female; D018734:Genes, erbB-2; D006801:Humans; D000077341:Lapatinib; D017239:Paclitaxel / Q000008:administration & dosage; D011799:Quinazolines / Q000008:administration & dosage
D011799:Quinazolines; D000077341:Lapatinib; D017239:Paclitaxel